We here investigated whether CD69+EVs may be conceived as surrogate markers of host CD69+ TRM_T cells burden in the pre-transplant phase and thus regarded as predictive markers of GVHD in ATLG-treated patients. The gene discussed is CD69; the disease is graft versus host disease.